PMID- 19840522
OWN - NLM
STAT- MEDLINE
DCOM- 20091207
LR  - 20211020
IS  - 1534-6269 (Electronic)
IS  - 1523-3790 (Linking)
VI  - 11
IP  - 6
DP  - 2009 Nov
TI  - Critical signaling pathways in bone sarcoma: candidates for therapeutic 
      interventions.
PG  - 446-53
AB  - Bone sarcomas cause disproportionate morbidity and mortality and desperately need 
      new therapies as there has been little improvement in outcomes in 20 years. 
      Identification of critical signaling pathways, including type 1 insulin-like 
      growth factor receptor (IGF-1R) for Ewing sarcoma and possibly osteosarcoma, and 
      the ERBB and the Wnt signaling pathways for osteosarcoma, have emerged as 
      receptors mediating vital signals for bone sarcoma. Akt, mammalian target of 
      rapamycin (mTOR), phosphoinositide 3-kinases, mitogen-activated protein kinase 
      kinase, extracellular signal-regulated kinases, and Ras pathway play key roles in 
      at least some tumors, and inhibition of mTOR in particular will likely lead to 
      improved survival, although clinical trials are still underway. The Notch pathway 
      and ezrin are essential for osteosarcoma metastasis, and Fas downregulation is 
      necessary for survival of metastases in lungs. As little is known about 
      chondrosarcoma signaling, more preclinical work is needed. By defining vital 
      signaling pathways in bone sarcomas, small molecule inhibitors can be applied 
      rationally, leading to longer survival and reducing morbidity and late effects 
      from intensive chemotherapy.
FAU - Geryk-Hall, Mandy
AU  - Geryk-Hall M
AD  - Department of Pediatrics Research, Unit 853, Children's Cancer Hospital, The 
      University of Texas, M. D. Anderson Cancer Center, PO Box 301402, Houston, TX 
      77030, USA.
FAU - Hughes, Dennis P M
AU  - Hughes DP
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Oncol Rep
JT  - Current oncology reports
JID - 100888967
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Bone Neoplasms/classification/*drug therapy
MH  - Humans
MH  - Receptors, Cell Surface/*drug effects/physiology
MH  - Sarcoma/classification/*drug therapy
MH  - Signal Transduction
EDAT- 2009/10/21 06:00
MHDA- 2009/12/16 06:00
CRDT- 2009/10/21 06:00
PHST- 2009/10/21 06:00 [entrez]
PHST- 2009/10/21 06:00 [pubmed]
PHST- 2009/12/16 06:00 [medline]
AID - 10.1007/s11912-009-0061-z [doi]
PST - ppublish
SO  - Curr Oncol Rep. 2009 Nov;11(6):446-53. doi: 10.1007/s11912-009-0061-z.